Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Short term Debt (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Short term Debt for 5 consecutive years, with $6.7 million as the latest value for Q3 2019.

  • On a quarterly basis, Short term Debt rose 9976.71% to $6.7 million in Q3 2019 year-over-year; TTM through Sep 2019 was $6.7 million, a 9976.71% increase, with the full-year FY2019 number at $6.7 million, up 9976.71% from a year prior.
  • Short term Debt was $6.7 million for Q3 2019 at Outlook Therapeutics, roughly flat from $6.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $12.2 million in Q4 2017 to a low of $50806.0 in Q2 2017.
  • A 5-year average of $2.7 million and a median of $747547.5 in 2015 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: crashed 93.25% in 2017, then skyrocketed 9976.71% in 2019.
  • Outlook Therapeutics' Short term Debt stood at $742646.0 in 2015, then soared by 564.34% to $4.9 million in 2016, then skyrocketed by 147.11% to $12.2 million in 2017, then dropped by 25.7% to $9.1 million in 2018, then dropped by 26.04% to $6.7 million in 2019.
  • Per Business Quant, the three most recent readings for OTLK's Short term Debt are $6.7 million (Q3 2019), $6.7 million (Q2 2019), and $1.1 million (Q1 2019).